deltatrials
Unknown PHASE1/PHASE2 INTERVENTIONAL 1-arm NCT03706287

Efficacy and Safety of Anlotinib Plus Platinum Plus Pemetrexed in T790M-negative NSCLC

Efficacy and Safety of Anlotinib Combined With Platinum Plus Pemetrexed in T790M Mutation Negative Metastastic Non-squamous Non-small-cell Lung Cancer After Progression on First-line EGFR TKI: a Phase II, Muti-center, Single Arm Study

Sponsor: Chia Tai Tianqing Pharmaceutical Group Co., Ltd.

Conditions Lung Cancer Metastatic
Interventions anlotinib + AP/PC anlotinib 10mg + AP/PC anlotinib 12mg + AP/PC anlotinib 8mg + AP/PC
Updated 6 times since 2018 Last updated: Apr 2, 2020 Started: Dec 6, 2018 Primary completion: Mar 10, 2021 Completion: Mar 10, 2021
This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

This PHASE1/PHASE2 trial investigates Lung Cancer Metastatic and is currently ongoing. Chia Tai Tianqing Pharmaceutical Group Co., Ltd. leads this study, which shows 6 recorded versions since 2018 — indicating limited longitudinal coverage. As an oncology study, it adds to the longitudinal record of treatment development for this indication.

Status Flow

~Nov 2018 – ~May 2020 · 18 months · monthly snapshotNot Yet Recruiting~May 2020 – ~Jan 2021 · 8 months · monthly snapshotRecruiting~Jan 2021 – ~May 2022 · 16 months · monthly snapshotRecruiting~May 2022 – ~Jul 2024 · 26 months · monthly snapshotUnknown Status~Jul 2024 – ~Sep 2024 · 2 months · monthly snapshotUnknown~Sep 2024 – present · 21 months · monthly snapshotUnknown

Change History

6 versions recorded

  1. Sep 2024 — Present [monthly]

    Unknown PHASE1/PHASE2

  2. Jul 2024 — Sep 2024 [monthly]

    Unknown PHASE1/PHASE2

    Status: Unknown Status → Unknown · Phase: PHASE1_PHASE2 → PHASE1/PHASE2

  3. May 2022 — Jul 2024 [monthly]

    Unknown Status PHASE1_PHASE2

    Status: Recruiting → Unknown Status

  4. Jan 2021 — May 2022 [monthly]

    Recruiting PHASE1_PHASE2

  5. May 2020 — Jan 2021 [monthly]

    Recruiting PHASE1_PHASE2

    Status: Not Yet Recruiting → Recruiting

▶ Show 1 earlier version

  1. Nov 2018 — May 2020 [monthly]

    Not Yet Recruiting PHASE1_PHASE2

    First recorded

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:
  • Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
  • Sichuan Cancer Hospital and Research Institute
Data source: Sichuan Cancer Hospital and Research Institute

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations